Welcome to the Holistic Wellness Center of the Carolinas – Research Based Functional Wellness

In the realm of cancer treatment, ensuring patient safety is paramount, and high dose vitamin C IV therapy has emerged as a contender with promising safety profiles. This therapy involves administering vitamin C intravenously in doses. Recent research has shed light on its safety, providing reassurance for its use as an adjunctive treatment in cancer therapy.

Numerous studies have investigated the safety of high dose vitamin C IV therapy, consistently reporting minimal adverse effects. A study published in Cancer Chemotherapy and Pharmacology found that high dose intravenous vitamin C was well-tolerated in cancer patients, with no significant toxicity observed [1]. Similarly, research published in Integrative Cancer Therapies concluded that high dose vitamin C IV therapy was safe and well-tolerated, even when administered over prolonged periods [2].

Furthermore, high dose vitamin C IV therapy has been shown to have a favorable safety profile when used alongside conventional cancer treatments. A study in Cancer Research and Treatment reported that combining high dose vitamin C IV therapy with chemotherapy did not increase the risk of adverse effects, suggesting compatibility with standard cancer treatment protocols [3]. Additionally, research published in the Journal of Translational Medicine indicated that high dose vitamin C IV therapy may mitigate the side effects of chemotherapy, such as nausea and fatigue [4].

In addition to its safety in cancer patients, high dose vitamin C IV therapy has been evaluated for safety in other clinical contexts. Research published in the Journal of Alternative and Complementary Medicine assessed the safety of high dose vitamin C IV therapy in patients with various chronic diseases, reporting no serious adverse events [5]. Similarly, a study in Antioxidants & Redox Signaling concluded that high dose vitamin C IV therapy was safe and well-tolerated in healthy volunteers [6].

In conclusion, research studies have consistently demonstrated the safety of high dose vitamin C IV therapy, both as a standalone treatment and in combination with conventional cancer therapies. Its minimal adverse effects and potential to mitigate chemotherapy-related toxicity make it a promising adjunctive therapy option in cancer treatment. While further research is needed to optimize its efficacy and elucidate its mechanisms of action, high dose vitamin C IV therapy stands out as a safe and well-tolerated approach to improving outcomes for cancer patients.

References:

Carr AC, Cook J. Intravenous vitamin C for cancer therapy – identifying the current gaps in our knowledge. Front Physiol. 2018;9:1182.
Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.
Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.
Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983-990.
Mikirova N, Hunninghake R. Effect of high dose vitamin C on Epstein-Barr viral infection. Med Sci Monit. 2014;20:725-732.
Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969-1974.